靶向 ROR1 的抗体药物偶联物 zilovertamab vedotin 和 VLS-211 对 B 细胞急性淋巴细胞白血病患者来源异种移植模型的临床前评价

Preclinical evaluation of the ROR1-targeting antibody-drug conjugates zilovertamab vedotin and VLS-211 against B-cell ALL patient-derived xenografts.

慢性淋巴细胞白血病中的 Richter 转化：当前治疗挑战与不断演变的疗法

Richter Transformation in Chronic Lymphocytic Leukemia: Current Treatment Challenges and Evolving Therapies.

RORing CAR-T 细胞在实体瘤与血液肿瘤中：相同却不同

RORing CAR T Cells in Solid and Hematologic Cancers: Same but Different.

ROR1 特异性 CAR-T 细胞治疗晚期血液系统与上皮恶性肿瘤的 I 期研究

Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies.

ROR1 CAR-T 细胞在大多数患者中耐受良好。

各种成人白血病和淋巴瘤类型中 ROR1 水平的肿瘤评估

Tumour assessment of ROR1 levels in various adult leukaemia and lymphoma types.

释放潜力：ROR1 靶向肿瘤治疗的进展与未来前景

Unlocking the potential: advancements and future horizons in ROR1-targeted cancer therapies.

骨髓来源间充质基质细胞阻碍靶向 AML 的 CD8(+) 克隆效应细胞和 CAR-T 细胞功能，同时促进衰老相关表型

Bone marrow-derived mesenchymal stromal cells obstruct AML-targeting CD8(+) clonal effector and CAR T-cell function while promoting a senescence-assoc

ICOS 和 OX40 串联共刺激增强 CAR-T 细胞细胞毒性并促进 T 细胞持久性表型

ICOS and OX40 tandem co-stimulation enhances CAR T-cell cytotoxicity and promotes T-cell persistence phenotype.

抗 ROR1 CAR-T 细胞：结构与性能

Anti-ROR1 CAR-T cells: Architecture and performance.

B 细胞淋巴系统恶性肿瘤的 CAR-T 细胞治疗：识别 CD19 之外的靶点

CAR-T cell Therapies for B-cell Lymphoid Malignancies: Identifying Targets Beyond CD19.